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Introduction
The Consolidated Standards of Reporting Trials (CONSORT) 
Guidelines were created in 1996 and most recently updated in 2010 
[1,2].  The guidelines were specifically developed to alleviate the problem 
of inadequate reporting of randomized controlled trials (RCTs), which 
is associated with bias in estimating the effectiveness of interventions 
[2,3]. CONSORT strongly recommends and encourages transparency 
with reporting methods and results so that readers can accurately 
interpret and assess strengths and limitations of the studies [4-8]. 
Several follow-up studies have noted a positive effect of the guideline 
recommendations on the overall reporting of RCTs [5,7]. One of the 
recommendations of CONSORT is the inclusion of a flow diagram 
that maps the path of each study subject through the entire trial, from 
randomization to analysis and follow-up [2].  The CONSORT flow 
diagram not only enables readers to more easily track the number 
of participants, but it also assists in determining if intention-to-treat 
(ITT) analysis was carried out by evaluating a structure and process 
of the study population in the RCT and its attrition.  Although many 
journals have adopted CONSORT as part of their submission criteria, 
published articles from literature indicate that many RCTs do not 
include the recommended CONSORT flow diagram in the publication 
[9,10] and even fewer studies reported associations between the 
COSORT compliance and the CONSORT endorsement by journals. 
As disproportionate attrition of the patients with various reasons 
such as missing data, loss to follow up, adverse drug effects, and others, 
can distort the initial randomization scheme and potentially threaten 
the internal validity of the study, which can subsequently lead to an 
inaccurate conclusion and inappropriate application to clinical practice 
[11,12], this  study was prepared to assess the level of CONSORT 
compliance by including a flow diagram, to describe the extent of 
attrition during the stages of study subject enrollment, allocation, loss 
to follow-up, and analysis, and to evaluate an association between 
the CONSORT compliance and the CONSORT endorsement by 
journals. Our study focused on infectious diseases because RCTs in the 
diseases often include more than one analytic group, such as clinical or 
microbiologic outcomes, which requires additional descriptions about 
attrition of their study population.    
Methods
Data sources and search
A cross sectional evaluation using a systematic literature search was 
conducted among all English publications of RCTs of anti-infective 
agents in the top 10 general medicine journals and the top 5 infectious 
disease journals with highest impact factors, which yielded a total of 14 
journals as one journal belonged to both groups. The journals were the 
New England Journal of Medicine, Journal of the American Medical 
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Abstract
Background:  The Consolidated Standard of Reporting Trials (CONSORT) Guidelines were developed to 
support adequate reporting of randomized controlled trials (RCTs). 
Method: A systematic review was conducted including RCTs of infectious diseases published in the top general 
medical and infectious disease journals in 2010. The level of compliance to flow diagram and its association with the 
CONSORT endorsement by the journals were evaluated. 
Results: A total of 67 studies were included in the analysis and a half of the studies were HIV/AIDS RCTs. 
About 78% of the studies included the flow diagram and 66% of the studies described an intention-to-treat approach. 
However, explicit descriptions of the study populations were the most lacking during the follow-up stage. The journals 
that endorsed the CONSORT statement had significantly lower odds of including the CONSORT flow diagram as 
compared with non-endorsing journals (OR=0.144; 95% CI 0.036-0.575, p<0.05). 
Conclusions:  About one out of four published RCTs in the top medical- and infectious disease journals did not 
include the CONSORT diagram in 2010, and inconsistency in the reporting of the study population was observed. 
Clear and complete description of the attrition, especially on the follow-up process, can enhance valid interpretations 
of the findings by clinical pharmacists.
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Association, British Medical Journal (Clinical Research Ed), Archives 
of Internal Medicine, PloS Medicine, Annals of Internal Medicine, 
Clinical Infectious Diseases, the Journal of Infectious Diseases, the 
Lancet Infectious Diseases, AIDS, Emerging Infectious Diseases 
Journal, Annual Review of Medicine, Canadian Medical Association 
Journal, and Annals of Medicine Journal. The review was made on 
the published articles from January 1, 2010 to December 31, 2010 and 
search terms included randomized controlled trials in combination 
with the Medical Subject Headings for “anti-infective agents.” 
Endorsement status of the CONSORT by the journals in year 2010 was 
determined by the endorsement status indicated from the CONSORT 
website on the access date [13], communication with the editor’s office 
of each journal, and instruction to the authors to adhere to CONSORT 
statement from the journal.  Priority was given to responses from the 
editor’s office, and “endorsed” status was considered if two or more 
sources of the information were consistent. 
Study selection and data analysis
Medline search identified 129 articles from 14 different journals. 
Following exclusion criteria, 67 articles were selected for further review 
to determine their eligibility based on the criteria of being 1) randomized 
controlled study design and 2) original research on infectious disease. 
Compliance to the CONSORT statement on participant flow in the 
results section [1,2] was determined by inclusion of one or more 
flow diagrams describing the study population.  The CONSORT flow 
diagram accounted for the stages of enrollment, allocation, follow-up, 
and analysis. To further describe the level of CONSORT compliance by 
each stage, compliance was determined in three levels (i.e., complete, 
partial, and missing). If the study fully accounted for the number of 
the participants and gave specific reasons in each stage, the study was 
considered “complete” compliance in the specific stage.  “Partial” 
status was defined if the stage description did not completely provide 
information on the number of excluded participants or reasons but 
did include some information. “Missing” status was defined if the 
stage description did not include any information on the number 
of participants or reasons for exclusion. Information on the extent 
of attrition, and employment of ITT analysis was collected and 
summarized from CONSORT flow diagrams as well as from body text 
of the articles. 
Analytic goals of our study were primarily reporting results from 
the descriptive analyses on frequency or proportion of CONSORT 
compliance by stage and journal type. Multivariate logistic regression 
was conducted to determine potential predictive factors for CONSORT 
compliance of including a flow diagram and adjusted ORs were 
calculated. The significance level of the multivariate analysis was set 
at 0.05 and the analysis was performed with SPSS statistical software, 
version 20 (SPSS Inc, Chicago, IL).
Results
The study identified 129 RCT articles published from January 1st 
to December 31st in 2010 from the selected 14 journals and only 67 
RCTs from 9 journals met the inclusion criteria (Figure 1). Of the 67 
infectious disease RCTs, 52 articles (77.61%) included the CONSORT 
flow diagram.  Forty-four (65.67%) articles described an ITT approach 
in their methods (Figure 1). About a half (50.75%) of the selected 
articles were HIV/AIDS, followed by malarial infection (8.96%) or 
parasitic infection (8.96%) Table 1. 
The selected articles were evaluated for CONSORT compliance 
by evaluating the inclusion of participant flow diagrams and the level 
of the compliance in each stage of the CONSORT descriptions. Of 
the 52 RCTs that included the CONSORT participant flow diagram, 
higher proportions of the articles included ‘complete’ descriptions on 
stages of enrollment (40 studies or 76.92%) and allocation (44 studies 
or 84.61%). However, smaller number of studies included ‘complete’ 
descriptions on the follow-up stage (16 studies or 30.76%) Figure 2. 
Journals that did not endorse CONSRT guidelines include the 
Clinical Infectious Diseases journal, the Lancet Infectious Diseases 
journal, and the New England Journal of Medicine journal during the 
study period and they accounted 53.7% (36 out of 67 articles) of the 
total number of articles (Table 2).  Of the 52 articles that included the 
CONSORT flow diagram, 33 (64.5%) were published in journals not 
endorsing CONSORT Statement in their instruction to the authors 
(Table 2).  Findings from our study also showed that the CONSORT 
endorsement by the journal was a negative predictor for including 
CONSORT participant flow diagram. (ORadj=0.144; 95% CI 0.036-
0.575, p<0.05).   
Discussion
Our study provides a snapshot assessment of the level of compliance 
to the CONSORT statement on participant flow by including a flow 
diagram from published RCTs of infectious diseases in 2010.  A 
comprehensive CONSORT flow diagram reduces the time for readers 
like clinical pharmacists to follow the flow of the study participants 
so that key information related to study subjects in each phase of the 
clinical trial can be captured so that clinicians could make an accurate 
interpretation and assessment of the strengths and limitations of the 
findings from RCTs [4-8] to be applied to pharmacy practice.
From the results of our study, over three out of four RCTs included 
a CONSORT flow diagram. Our findings corroborate with other 
published studies from non-infectious diseases – such as obstetric 
anesthesia (89%)[14], respiratory disease (69%) [15], acute and chronic 
myeloid leukemia, and myelodysplastic syndromes (89%) [16], and 
restless legs syndrome (88.9%) [17].  While our study reported that 
majority of the  articles with CONSORT participation flow diagrams 
were from non-CONSORT endorsing  journals, our results are not 
consistent to those reported by Hopewell et al. [18] reporting that 
90.11% of studies with the diagram were published in CONSORT-
endorsing journals. 
Our review also showed that the reporting of the integral elements 
of the RCTs in the flow diagram was lacking.  In the elements examined, 
i.e. overall number of people screened for study eligibility, the number 
of people that were randomized, the number of people allocated to 
either control group or intervention group, and the overall number 
of people analyzed, variabilities in the level of descriptions about the 
study participants were demonstrated, particularly for the numbers 
in the follow-up and the analysis phases. Details of the attrition rate 
of the participants or those who discontinued the intervention were 
poorly accounted for; only 30% of the trials reported the overall 
number of lost-to-follow-up, which can lead to bias in estimating 
the effectiveness of interventions, thereby undermining the aim of 
CONSORT [2,3].  The variability in the clear reporting of the elements 
of the flow diagram was not limited to our study.  A study by Kehoe 
et al on nutrition and pregnancy found that only 31% of their studies 
reported the overall number of people screened for study eligibility 
[19]. Follow-up analyses as well as analyses of the groups to which 
subjects were originally allocated are usually included as part of good 
research method practices [20].
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129 articles identified 
From 14 journals 58 articles excluded 
Non randomized trials (n=55) 
No control group (n=3) 
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Yes (n =44) 
No (n =23) 
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From 9 journals 
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71 RCTs reviewed  
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Figure 1: Flow diagram of RCTs included in the study
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Figure 2: The level of CONSORT compliance*
*Complete: The study fully accounted for the number of the participants and gave reasons.  Partial: The study did not completely provided information on the number 
of excluded participants or reasons.  Missing: The section was not provided.
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missing population to investigate the effect of the missing data from the 
assumption made in the ITT analyses [27,28]. 
This study has a few limitations.  Our evaluation was limited to 
RCTs involving anti-infective agents, publications in English language, 
and trials published in the highest impact factor general medicine and 
infectious diseases journals.  Therefore, our findings might not be a true 
representative of all published studies of RCTs or clinical conditions. 
“CONSORT 2010 Explanation and Elaboration: updated guidelines for 
reporting parallel group randomized trials” was published 24 March 
2010 [3].  Although there was a time gap between the time the updated 
guidelines were published and the search of our study, inclusion of the 
flow diagram were consistently recommended and the progress of the 
trial was divided into four stages of enrollment, allocation, follow-up, 
and analysis in the 2001 and 2010 guidelines [1,2]. 
Conclusion 
In conclusion, about one out of four published RCTs in the 
highest impact factor medical- and infectious disease journals did 
not include the CONSORT participant flow diagrams in 2010 and the 
CONSORT endorsement by the journal was not a positive predictor 
for the inclusion of the diagram. Clear and complete description of 
the attrition, especially on the follow-up process, can enhance valid 
interpretations of the findings by clinical pharmacists. Further studies 
are needed to explore if similar patterns are observed from other 
clinical conditions.
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that statistical analysis may make unreasonable assumptions when data 
are incomplete or missing [25].  
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